Related Experiment Video
Updated: Mar 24, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Kurt A Schalper1, Edward Kaftan2, Roy S Herbst3
1Department of Pathology, Yale School of Medicine, New Haven, Connecticut. Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut. Translational Immuno-oncology Laboratory, Yale Cancer Center, New Haven, Connecticut. kurt.schalper@yale.edu.
Abstract:
Blockade of the PD-1 axis has emerged as an effective anticancer immunotherapy against various tumor types. Diverse studies have identified biomarkers associated with response to these therapies. However, the clinical use of such tests is limited by their variable performance and restricted understanding of their biologic significance. Clin Cancer Res; 22(9); 2102-4. ©2016 AACRSee related article by Ock et al., p. 2261.
